Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Yitzhak Zimmer

Showing results (21-30 of 47) with videos related to

Pageof 5
Sort By:
Biochemical and Biophysical Research Communications|January 15, 2013
Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cellsMagali Humbert, Michaela Medová, Daniel M Aebersold, et al.
FEBS Letters|January 21, 2014
Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulationDominic Leiser, Benoît Pochon, Wieslawa Blank-Liss, et al.
Clinical & Experimental Metastasis|July 30, 2009
MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancersPirus Ghadjar, Wieslawa Blank-Liss, Mathew Simcock, et al.
Cancer Letters|September 29, 2009
Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274Yitzhak Zimmer, Angelina V Vaseva, Michaela Medová, et al.
International Journal of Radiation Oncology, Biology, Physics|March 17, 2010
Incidence of small lymph node metastases with evidence of extracapsular extension: clinical implications in patients with head and neck squamous cell carcinomaPirus Ghadjar, Mathew Simcock, Heide Schreiber-Facklam, et al.
Molecular Cancer|May 24, 2017
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer modelsLluís Nisa, Pascal Häfliger, Michaela Poliaková, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric CancerPaola Francica, Lluís Nisa, Daniel M Aebersold, et al.
Scientific Reports|February 4, 2017
Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cellsIzabela Nita, Katrin Hostettler, Luca Tamo, et al.
Genome Research|February 12, 2021
Enhancing CRISPR deletion via pharmacological delay of DNA-PKcsNúria Bosch-Guiteras, Tina Uroda, Hugo A Guillen-Ramirez, et al.
Molecular Cancer Therapeutics|September 25, 2013
The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variantsMichaela Medová, Benoît Pochon, Bruno Streit, et al.
Pageof 5

Showing results (21-30 of 47) with videos related to

Sort By:
Pageof 5
Biochemical and Biophysical Research Communications|January 15, 2013
Protective autophagy is involved in resistance towards MET inhibitors in human gastric adenocarcinoma cellsMagali Humbert, Michaela Medová, Daniel M Aebersold, et al.
FEBS Letters|January 21, 2014
Targeting of the MET receptor tyrosine kinase by small molecule inhibitors leads to MET accumulation by impairing the receptor downregulationDominic Leiser, Benoît Pochon, Wieslawa Blank-Liss, et al.
Clinical & Experimental Metastasis|July 30, 2009
MET Y1253D-activating point mutation and development of distant metastasis in advanced head and neck cancersPirus Ghadjar, Wieslawa Blank-Liss, Mathew Simcock, et al.
Cancer Letters|September 29, 2009
Differential inhibition sensitivities of MET mutants to the small molecule inhibitor SU11274Yitzhak Zimmer, Angelina V Vaseva, Michaela Medová, et al.
International Journal of Radiation Oncology, Biology, Physics|March 17, 2010
Incidence of small lymph node metastases with evidence of extracapsular extension: clinical implications in patients with head and neck squamous cell carcinomaPirus Ghadjar, Mathew Simcock, Heide Schreiber-Facklam, et al.
Molecular Cancer|May 24, 2017
PIK3CA hotspot mutations differentially impact responses to MET targeting in MET-driven and non-driven preclinical cancer modelsLluís Nisa, Pascal Häfliger, Michaela Poliaková, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|May 18, 2016
Depletion of FOXM1 via MET Targeting Underlies Establishment of a DNA Damage-Induced Senescence Program in Gastric CancerPaola Francica, Lluís Nisa, Daniel M Aebersold, et al.
Scientific Reports|February 4, 2017
Hepatocyte growth factor secreted by bone marrow stem cell reduce ER stress and improves repair in alveolar epithelial II cellsIzabela Nita, Katrin Hostettler, Luca Tamo, et al.
Genome Research|February 12, 2021
Enhancing CRISPR deletion via pharmacological delay of DNA-PKcsNúria Bosch-Guiteras, Tina Uroda, Hugo A Guillen-Ramirez, et al.
Molecular Cancer Therapeutics|September 25, 2013
The novel ATP-competitive inhibitor of the MET hepatocyte growth factor receptor EMD1214063 displays inhibitory activity against selected MET-mutated variantsMichaela Medová, Benoît Pochon, Bruno Streit, et al.
Pageof 5